Yes! ISIS-FXI Rx license to Bayer
A couple of points to keep in mind. This deal with Bayer makes an additional partner that is added to the fray to help ISIS avoid a takeover. We don't know but if ISIS were to go into more blood dyscrasia type diseases Bayer could become a major partner. Will be interesting to see what term Dr. Crooke uses in describing them tomorrow as a partner.
I'm a little disappointed in the up-front payment, but until we hear all of the fine details tomorrow I'll reserve judgment it could be better than expected in other ways. There could be a "moving clause" that allows ISIS to get more money from any undiscovered indications if they should come up. I do think that the editorial article in the NEJM could have hurt the pricing alittle as the NEJM has that excellent reputation and it was put out by the editor of the prestigious journal...even if he showed some of his ignorance at the time to us.
The situation that you describe CC in regards to the cost of goods and risk there....with ISIS new oligonuceotide factory they have cut the cost of their manufacturing down by 10-fold. If you were to use a LICA product that would increase the potency by 10-fold so you have a 100 fold decrease compared to if ISIS were to try and develop this drug by themselves just four years ago. If it is possible for a follow on 2.5 version drug then that would be another 10 fold decrease in price resulting in a 1000 fold reduction in costs compared to just four years ago.
A huge indication, that I'm not really counting yet but will pursue at the annual meeting will be those patients that have atrial fibrillation WITH valvular replacement. That alone could make this drug a blockbuster. Remember ISIS went through all of the coagulation factors and discovered that this one, Factor XI allowed for no bleeding with anticoagulation properties. The big if will be does it anti-coagulate better than the Factor Xa inhibitors without the bleeding. t
Baxter International (BAX) and Merrimack Pharmaceuticals (MACK) jointly announced that Baxter has submitted a marketing authorization application (MAA) to the European Medicines Agency for approval of MM-398, also known as ''nal-IRI,'' an investigational treatment for patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy
The market is saying that even though ANS isn't perfect, as no medicines are, the market is saying that ISIS RNA meds have huge potential. While you are over here instead of being on your own website I'm going to bring all of the vicl info to you. That way you and the Chums may be able to save face and a certain amount of money that seems to be getting smaller by the month by squarely placing your bets on vicl. t
Chums, I'm going to listen to this Friday's CC and report findings here because you guys don't reside in the usual area one would expect...that being the vicl board. I'll give you an honest opinion of whether I think you are betting on plug or a real thorough bred when you continue to hold what seems to be an extremely bad dog/plug horse. I can't recommend enough that you sell half of your vicl now and let's see what the CC shows to be the future. I just wish that vj would help bankroll your commune so that you would have some place to go should vicl go down the tubes as most experts I check with expect to happen. That includes technicians, biotech analysts, feng-shui experts, and other people in biotech. The sooner you leave this dinosaur the better, but let's give it a last chance. t
Chums, let's all listen to the CC on vicl on Friday to see what they have to offer. What we need to know Chums is what is on the docket and how can management convince you that their technology still holds some promise and what time lines do they have for some potential success. Chums, if it isn't there on Friday in a convincing manner it isn't going to be there. Even getting 90cents a share is better than 30cents a share or lower when you try to back out of your position on the pink sheets. Then maybe you can go on Shark Tank with your plan to open up the worm farms, worm food, and worm clothes. That Mark Cuban invested in some company that uses cricket protein to be eaten by humans so there is always hope. t
Chums, I appeal to you to set a date as to when you decide that vicl is a dog. One of the Chums has noted that there will be big news by this summer. When this summer? How long do you hold onto a dog if the dog doesn't bark?? You'll save face and your bank account by deciding when that will happen that you'll face the fact that maybe this investment in vicl isn't too good. If you Chums would have sold back when vicl was a buck forty six you'd all maybe be able to get your own apartments and have cars. Things are looking bleaker and bleaker. If you can't afford dental care when your car gets stuck and someone asks you what happened you'll have to say that "the car was pinning and pinning in the mud." Don't let that happen, please set a date for selling the old gray plug if it doesn't come around by Sept 1st. Otherwise you'll be pinning and pinning yourself. t
Everything is relative. Here are some of the bigger biotechs that didn't fare as well as RNN did this week.
Healthcare: CLDN (2.62 -80.85%), IG (5.22 -41.61%), ATRA (40.45 -32.46%), AERI (9.37 -27.2%), ADXS (17.07 -26.86%), CALA (9.82 -26.77%), ARAY (6.82 -25.23%), RGLS (13.47 -22.98%), HRTX (11.01 -22.36%), AKRX (43 -22.16%), TKMR (14.67 -21.76%), JUNO (44.82 -20.9%)
Land might be cheap there, but the water situation isn't too good. Speaking of not too good, vicl lost another 3 cents today to close at 92 cents. The clock is ticking before the release of the warning letter for delisting. The Chums could get squeezed on a bigger water bill, and less life savings by holding the viacl bad. Maybe they could sell the name vicl to Glad wraps for extra large sandwiches like the one the Chums ate with the buying of the antifungal drug. t
tudywad, Thank you so much for your concern. I'm doing well, I hope you chums are also doing well. Please tudywad before you have to change your underalls multiple times, please sell vicl so that you have something to hand down to your parakeet. It is tough out there with no seed money. t
Crusoeandrobin, Did occur to you that this one little payment of $10 million is worth more than vicl has made in over 5 years for milestone payments. Now with the pxx-pxx sandwich swallowed and your $4 million dollar once in a fortnight being digested by wall street vicl really took it on the chin today. I sure hope you Chums sell vicl and get out while you still have some money before it hits the pink sheets. The clock is running as long as it stays below a buck. Please send pictures of potential commune locales and let us vote on which one is best for the Chums. t
Triple-negative breast cancers (TNBCs) are clinically aggressive tumors with limited treatment options. We examined the clinicopathological associations and prognostic implications of FGFR1 and FGFR2 expression in TNBCs. Tissue microarrays constructed from TNBCs were immunostained with FGFR1 and FGFR2, and scored by intensity and percentage of tumor cells stained per intensity for each subcellular compartment, which were correlated with clinicopathological parameters and survival. Cell migration following siRNA-mediated silencing of the FGFR1 gene in TNBC cell lines was also performed. 714 cases were informative for FGFR1 and FGFR2 immunostaining. Thresholds were defined as at least 1 % of cells stained and H-score of 100 or more. Proportions positive by each threshold were, respectively, 89.9 %, 7.1 % for FGFR1 (cytoplasm); 36.8 %, 7.8 % for FGFR2 (cytoplasm); and 33.5 %, 5.2 % for FGFR2 (membrane). Significant associations included FGFR1 and FGFR2 immunostaining for lobular subtype, FGFR2 immunostaining with lower grade, and more basal-like cancers with H-scores of 100 or more FGFR1 immunostaining. Multivariate Cox regression analysis showed FGFR1 expression in TNBCs to be independently prognostic for overall survival (OS) at both thresholds. Cases completely negative (less than 1 % staining) for FGFR1 immunostaining showed improved OS, while those with H-score of 100 or more immunostaining had the worst OS. Cell line studies revealed up-regulation of the FGFR1 gene in the MDA-MB-231 and Hs578T TNBC cells, and specific knockdown of FGFR1 expression significantly reduced cell migration in MDA-MB-231 cell line. In conclusion, FGFR1 expression in TNBCs is independently prognostic of OS, and H-score of 100 or more FGFR1 immunostaining may define tumors that have treatment potential via FGFR signaling inhibition.
Circulating cell-free miRNAs as biomarker for triple-negative breast cancer
British Journal of Cancer, 04/29/2015
Shin VY, et al.
This study suggest that miR–199a–5p could be a TNBC–specific marker with diagnostic value and provide insights into targeted therapy in the treatment of TNBC.
By using miRCURY LNA array platform, the authors compared the differential miRNA expressions in plasma of patient with TNBC (n=5) and non–TNBC (n=5), as well as healthy controls (n=5).
Potential miRNAs were then validated in a large cohort of patients by real–time PCR.
Ten putative miRNAs from the microarray data that differentially expressed between non–TNBC and healthy controls were identified.
In the screening phase (n=90), they selected five miRNAs (miR–92a–3p, miR–342–3p, miR–16, miR–21 and miR–199a–5p) that could discriminate TNBC from non–TNBC for further validation.
Results showed that miR–16, miR–21 and miR–199a–5p were underexpressed in TNBC when compared with non–TNBC, and were further validated in a large cohort (n=252).
In addition, post–operative plasma levels of miR–16, miR–21 and miR–199a–5p were significantly restored when compared with pre–operative plasma of TNBC.
Plasma miR–199a–5p expression in TNBC had significant difference when compared with non–TNBC and healthy controls, the receiver–operator characteristics curve analysis revealed the highest area under curve (AUC=0.8838) among all.
The expression levels were associated with TNM stage and tumour subtypes.
Hey KG, you to see you are coming over here. IMO things do look potentially very bright from a risk/reward ratio. Hope you are doing well. Get a hold of G and let's get together soon. t
Point out both sides, the fact that RNN has maintained its price in spite of the general biotech decline does show a certain amount of strength. t
Icehole, you are really out of here....nah, but if you aren't at least say prune head or prune juice to prime the pump for further appreciation once the biotech scare goes away. BTW, any comments in regards to why vicl is now down below a buck again even though they got a pxx-pxx sandwich from Astellas and that huge $4 million dollar payment??
Full recovery?? The patient suffered two small CVA's. Vitamin E levels that go to zero?! Ever hear of the possibility of deafness with low Vitamin E levels?? t
BIIB, ISIS, ALNY, and others all down fairly well today. RNN doing well, I think it is due to expectant news coming soon. t
Thank you for the Voo Doo code word. Hueyknowslittle, you are right, you Chums should forget it and move on, not many people believe in what you are saying in regards to the future for ISIS. Maybe hang around for a little while though as ISIS shoots past 80. Thank you for the prune head word, just as you said it ISIS turned positive. Thank you again, t